For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) closed at $1.65 in the last session, up 1.23% from day before closing price of $1.63. In other words, the price has increased by $1.23 from its previous closing price. On the day, 2.99 million shares were traded. LXRX stock price reached its highest trading level at $1.69 during the session, while it also had its lowest trading level at $1.605.
Ratios:
We take a closer look at LXRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.58 and its Current Ratio is at 5.60. In the meantime, Its Debt-to-Equity ratio is 1.14 whereas as Long-Term Debt/Eq ratio is at 1.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on March 07, 2023, initiated with a Hold rating and assigned the stock a target price of $3.
On August 12, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.
JP Morgan Upgraded its Underweight to Neutral on January 29, 2021, while the target price for the stock was maintained at $7.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 16 ’23 when COATS LONNEL bought 90,000 shares for $1.05 per share. The transaction valued at 94,797 led to the insider holds 914,359 shares of the business.
COATS LONNEL bought 10,000 shares of LXRX for $10,100 on Nov 10 ’23. The Chief Executive Officer now owns 824,359 shares after completing the transaction at $1.01 per share. On Oct 12 ’23, another insider, DEBBANE RAYMOND, who serves as the Director of the company, bought 148,820 shares for $1.03 each. As a result, the insider paid 153,805 and bolstered with 1,340,847 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LXRX now has a Market Capitalization of 406291040 and an Enterprise Value of 342328640. For the stock, the TTM Price-to-Sale (P/S) ratio is 335.78 while its Price-to-Book (P/B) ratio in mrq is 4.34. Its current Enterprise Value per Revenue stands at 284.326 whereas that against EBITDA is -2.0.
Stock Price History:
Over the past 52 weeks, LXRX has reached a high of $3.79, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is -29.93%, while the 200-Day Moving Average is calculated to be -3.45%.
Shares Statistics:
According to the various share statistics, LXRX traded on average about 4.85M shares per day over the past 3-months and 3011510 shares per day over the past 10 days. A total of 244.92M shares are outstanding, with a floating share count of 239.55M. Insiders hold about 2.72% of the company’s shares, while institutions hold 26.65% stake in the company. Shares short for LXRX as of 1711584000 were 21913448 with a Short Ratio of 4.52, compared to 1709164800 on 21065496. Therefore, it implies a Short% of Shares Outstanding of 21913448 and a Short% of Float of 45.92.
Earnings Estimates
The current rating of Lexicon Pharmaceuticals Inc (LXRX) is the result of assessments by Lexicon Pharmaceuticals, Inc. analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $16.44, with high estimates of $3.08 and low estimates of $7.35.
